About the DNA Sequencing Products Market
DNA sequencing is categorized into first-generation, second- and next-generation, and emerging technologies. Emerging DNA sequencing technologies are cost-effective and offer more rapid and accurate results than other generation technologies. These technologies find application in the areas of diagnostics, drug and biomarker discovery, personalized medicine, and agriculture and animal research. Since its introduction in 2010, next-generation DNA sequencing has developed rapidly. It offers insights into various areas of science, particularly healthcare and genomic research. However, available DNA sequencing technologies create significant financial complications for laboratories, increasing the pressure on maintaining the expenses for biomedical research. This has increased the demand for less expensive instruments and the need for cost-effective procedures. It has also increased the emphasis on enhancing aspects of sample preparation and expanding the simplicity of the work process for greater proficiency.
Technavio’s analysts forecast the global DNA sequencing products market to grow at a CAGR of 18.75% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global DNA sequencing products market for 2016-2020. To calculate the market size, we consider revenue generated from the sale of equipment, reagents, and consumables used in DNA sequencing.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global DNA Sequencing Products Market 2016-2020
Technavio recognizes the following companies as the key players in the global DNA sequencing products market: Illumina, Thermo Fisher Scientific, Roche Diagnostics, and Pacific Biosciences.
Other Prominent Vendors in the market are: AC-Gen Reading Life, Agilent Technologies, Beckman Coulter, Cofactor Genomics, DNA Link, Eurofins MWG Operon, Expression Analysis, GE HealthCare, Otogenetics, and Oxford Nanopore.
Commenting on the report, an analyst from Technavio’s team said: “One trend that is expected to boost market growth in a big way is the advances in personalized medicine. Many medical facilities in developed countries and a few in developing countries are implementing DNA sequencing technologies in medical treatment. These facilities use sophisticated technologies and tools such as rapid DNA sequencer for large-scale and quantitative assessments of genomic sequences. These devices have helped make important research discoveries in the area of biomedical sciences. These research results are implemented in clinical settings, particularly in oncology, for the development of personalized medicine.”
According to the report, a key growth driver is the development of rapid sequencing platforms. DNA sequencing has a wide scope in medical diagnosis and personalized treatment options. Sanger and Gilbert methods are first-generation sequencing procedures that were previously used by researchers for genome mapping. Advances in this technology led to the development of second-generation sequencing methods such as pyrosequencing. Further advances led to the development of next-generation sequencing procedures such as Illumina sequencing and 454 sequencing methods. These methods involve the use of advanced technologies, leading to their wide use in various clinical areas.
Further, the report states that one challenge that could hamper market growth is the limitations of DNA sequencing technologies.
Illumina, Thermo Fisher Scientific, Roche Diagnostics, Pacific Biosciences, AC-Gen Reading Life, Agilent Technologies, Beckman Coulter, Cofactor Genomics, DNA Link, Eurofins MWG Operon, Expression Analysis, GE HealthCare, Otogenetics, Oxford Nanopore.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook